From the first engineered T cell receptor medicine to regulatory snubs over China-only data, 2022 was another action-packed year for the oncology drug development community.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
18 January 2023
In the version of this article initially published, there was an error in the last paragraph of the “Degraders make the grade” section, where in the text now reading “Among them, AstraZeneca announced positive results this October from a pair of studies showing that the oral SERD camizestrant improved progression-free survival...,” “camizestrant” appeared as “capivasertib”; the change has been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dolgin, E. Cancer drug approvals and setbacks in 2022. Nat Cancer 3, 1406–1408 (2022). https://doi.org/10.1038/s43018-022-00482-y
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-022-00482-y
